NCT02519036: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
- State
- Completed
- Phase
- Phase 1 and Phase 2
- People
- 46 taking part
- Started
- 6 Aug 2015
- Primary completion
- 8 Nov 2017
- Arms
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg, ISIS 443139 90 mg, ISIS 443139 120 mg
- Results
- Posted on the registry
- 6 Aug 2015: Trial started
- 10 Aug 2015: Trial registered
- 8 Nov 2017: Trial completed
- 31 May 2019: Trial results posted